THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) announces the outcome of the partially guaranteed rights issue of approximately SEK 200 million (the “Rights Issue”). The subscription period in the Rights Issue ended on 16 March 2026. The outcome shows that 77,082,970 ordinary shares, corresponding to approximately 60 percent of the offered ordinary shares, have been subscribed for by exercise of subscription rights in the Rights Issue. Additionally, applications for subscription of 3,096,716 ordinary shares without subscription rights, corresponding to approximately 2 percent of the offered ordinary shares, have been submitted. Therefore approximately 33 percent of the Rights Issue will be allocated to parties that have entered into guarantee commitments. The Rights Issue will provide the Company with approximately SEK 190 million before deduction of transaction costs related to the Rights Issue.
The Rights Issue encompassed 129,283,736 new ordinary shares, of which 77,082,970 ordinary shares, corresponding to approximately 60 percent of the offered ordinary shares, have been subscribed for by exercise of subscription rights. Additionally, applications for subscription of 3,096,716 ordinary shares without subscription rights have been submitted, corresponding to approximately 2 percent of the offered ordinary shares. Therefore, 42,400,960 ordinary shares, corresponding to approximately 33 percent of the Rights Issue, will be allocated to parties that have entered into guarantee commitments. The subscription price was SEK 1.55 per new ordinary share. Through the Rights Issue, the share capital will be increased by approximately SEK 13,620,072.33, from approximately SEK 30,300,707.56 to approximately SEK 43,920,779.89, by a new issue of 122,580,646 new ordinary shares, resulting in the total number of shares increasing from 272,706,357 shares to 395,287,003 shares. The number of ordinary shares will increase from 258,567,472 ordinary shares to 381,148,118 ordinary shares.[1]
Allotment of shares subscribed for without subscription rights will be made in accordance with the principles outlined in the disclosure document regarding the Rights Issue that was published by Oncopeptides on 26 February 2026. Around 18 March 2026, a settlement note will be sent to those who have received allotment of shares as confirmation of the allotment of shares subscribed for without subscription rights. No confirmation will be sent to subscribers who received no allotment. Payment for subscribed and allocated shares is to be made in cash in accordance with the instructions on the settlement note sent to those who have received allotment of shares. Nominee-registered shareholders will receive a notification of allotment in accordance with the respective nominee’s procedures.
The last day for trading in paid subscribed shares (BTA) will be on 23 March 2026. The first day of trading in the new shares on Nasdaq Stockholm is expected to be on or around 27 March 2026.
Lock-up undertakings
In connection with the Rights Issue, the Company has agreed to a lock-up undertaking, subject to customary exceptions, whereby the Company’s Board of Directors may not propose or resolve on any new share issuances for a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided, however, that the Company shall have the right to issue and transfer warrants to the European Investment Bank – EIB (in accordance with the agreement prior entered into between the Company and EIB). In addition, the members of the Board of Directors and senior management of Oncopeptides have agreed not to sell any shares in Oncopeptides for a period of 180 calendar days after the announcement of the outcome of the Rights Issue, subject to customary exceptions.
Advisors
DNB Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue. Advokatfirman Vinge KB is legal adviser to the Company.
[1] Oncopeptides holds 14,138,885 class C shares as part of the Company’s incentive programs. The class C shares did not entitle to participation in the Rights Issue.
